Rapid and Robust Derivation of Mesenchymal Stem Cells from Human Pluripotent Stem Cells Via Temporal Induction of Neuralized Ectoderm
Overview
Authors
Affiliations
Background: Mesenchymal stem cells (MSCs) are emerging as the mainstay of regenerative medicine because of their ability to differentiate into multiple cell lineages. The infinite proliferative potential of human pluripotent stem cells (PSCs) grants an unlimited supply of MSCs. Despite their great potential in therapeutic applications, several drawbacks have hindered its clinical translation, including limited number of replication, compromised potential and altered function in late passages. The aim of this study is to establish an efficient method for the production of MSCs from pluripotent stem cells for potential clinical application in rare human disease Hutchinson-Gilford progeria syndrome.
Results: We established a robust method allowing rapid derivation of MSCs from both human iPSCs and ESCs via a temporal induction of neural ectoderm in chemically defined media. The iPSC- and ESC-derived MSCs satisfy the standard criteria of surface markers. They exhibited a high tri-lineage differentiation potential with over 90% transcriptional similarity to the primary MSCs derived from bone marrow. To evaluate the potential application of this method in disease modeling, MSCs were generated from iPSCs derived from a patient with Hutchinson-Gilford progeria syndrome (HGPS-MSCs) and from mutation-rectified HGPS-iPSCs (cHGPS-MSCs). HGPS-MSCs manifested accelerated senescence whereas mutation rectification rescued cellular senescence in HGPS-MSCs.
Conclusions: The robust method of MSC derivation from ESCs and iPSCs provides an efficient approach to rapidly generate sufficient MSCs for in vitro disease modeling and clinical applications.
Jin W, Jiang S, Liu X, He Y, Li T, Ma J Nat Commun. 2024; 15(1):10046.
PMID: 39567511 PMC: 11579472. DOI: 10.1038/s41467-024-54338-3.
Targeting ATAD3A Phosphorylation Mediated by TBK1 Ameliorates Senescence-Associated Pathologies.
He Y, Liu Y, Zheng M, Zou Y, Huang M, Wang L Adv Sci (Weinh). 2024; 12(1):e2404109.
PMID: 39520088 PMC: 11714148. DOI: 10.1002/advs.202404109.
Alternative Ways to Obtain Human Mesenchymal Stem Cells from Embryonic Stem Cells.
Onyanov N, Glazova O, Sakr N, Krokunova T, Krupinova J, Volchkov P Cells. 2024; 13(19.
PMID: 39404381 PMC: 11476410. DOI: 10.3390/cells13191617.
A systematic review of clinical efficacy and safety of cell-based therapies in Alzheimer's disease.
Feizi H, Hosseini M, Seyedi-Sahebari S, Karimi H, Mosaddeghi-Heris R, Sadigh-Eteghad S Dement Neuropsychol. 2024; 18:e20240147.
PMID: 39258164 PMC: 11386524. DOI: 10.1590/1980-5764-DN-2024-0147.
Research progress of autoimmune diseases based on induced pluripotent stem cells.
Ren R, Jiang J, Li X, Zhang G Front Immunol. 2024; 15():1349138.
PMID: 38720903 PMC: 11076788. DOI: 10.3389/fimmu.2024.1349138.